Histones and their modifications are crucial for adaptation to cell stress Blog Post

The Cell Signaling laboratory at IRB Barcelona, ​​led by Eulàlia de Nadal and Francesc Posas at the Barcelona Science Park, has identified more than 200 regions (amino acids) in histones that are responsible for regulating the response to cell stress. The study reports that histones undergo distinct modifications depending on the type of cell stress.

 

SOM Biotech announces the in vitro confirmation of three drug candidates for COVID-19 with the Ewha Womans University Blog Post

SOM Biotech, a clinical-stage drug discovery and development company based in the Barcelona Science Park, announces the in vitro validation of three drug candidates as new therapies for the treatment of COVID-19 in collaboration with the Ewha Womans University in South Korea. A patent application has been filed to provide method of use protection for the three compounds worldwide. All three drugs can be repurposed to treat COVID-19 and the company is working on the fastest way to prove them in patients.

 

Juan Carlos Kaski, new Chief Medical Officer of GlyCardial Diagnostics Blog Post

GlyCardial Diagnostics, based in the Barcelona Science Park, announces the appointment of Prof. Juan Carlos Kaski as Chief Medical Officer. The company –a spinoff of the Research Institute of the Hospital de la Santa Creu i Sant Pau (IR-HSCSP) and the Spanish National Research Council (CSIC), is conducting a clinical trial to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of Myocardial Ischaemia.

 

AECC backs cancer research involving 3D models at IRB Barcelona Blog Post

The Asociación Española Contra el Cáncer (AECC) –in collaboration with Cancer Research UK (CRUK) and the Fondazione AIRC per la Ricerca sul Cancro (AIRC)– has awarded more than €500,000 euros of funding to an IRB Barcelona project, within the framework of the Accelerator Awards call.  the project will allow researchers to study the complexity and heterogeneity of cancer using culturable mini-cancers, also known as organoids, derived from patients.

 

Researchers from CNAG-CRG and IRB Barcelona contribute to the description of the most comprehensive map of cancer genomes Blog Post

The international team of scientists of the ‘Pan-Cancer Analysis of Whole Genomes Project’ (PCAWG) today published 23 studies in the Nature journals, describing the most comprehensive map of cancer genomes from 38 types of tumours to date. Among the 1,300 researchers who have contributed to the project are scientists from the Institute for Research in Biomedicine (IRB Barcelona) and the Centro Nacional de Análisis Genómico (CNAG-CRG) in the Barcelona Science Park.The results are an important step for the development of personalised medicine to treat cancer.

 

Núria López-Bigas receives the National ‘Doctores Diz Pintado’ Cancer Research Prize Blog Post

Núria López-Bigas, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona) in the Barcelona Science Park, has received the IX National ‘Doctores Diz Pintado’ Cancer Research Prize for her career path. The researcher is the first female scientist to be presented with this prize, which is presented every year by the Fundación de Investigación del Cáncer de la Universidad de la Salamancaa (FICUS)-Centro de Investigación del Cáncer (USAL-CSIC)  to promote and acknowledge the contribution of young Spanish researchers to Cancer Research.

 

Esteve acquires German pharmaceutical company Riemser and expands its presence in Europe Blog Post

Esteve have come to an agreement to acquire the German pharmaceutical company Riemser. Headquartered in Berlin, Riemser has subsidiaries in the United Kingdom, France, and Spain and is present in nearly 50 countries through alliances with third parties. This acquisition provides Esteve ––which has its Drug Discovery and Preclinical Development Center at the Barcelona Science Park–– with greater pharmaceutical presence in Europe’s main markets and a portfolio of proprietary specialty products for hospital use. 

 

Researchers from the CNAG-CRG develop a new classification system for tumours Blog Post

Based on the largest study of cancer patients of its kind, scientists at the Centre Nacional d’Anàlisi Genòmica (CNAG-CRG), located in the Barcelona Science Park, have created a new way of classifying tumours. Clinicians can use genome sequencing to assign their patients’ tumours to one of sixteen groups in the new classification system, ten of which provide important information for the diagnosis and treatment of the disease, like whether an individual will respond to immunotherapy. The work is published in PLOS Computational Biology.

 

Aerie Pharmaceuticals announces agreement to acquire Avizorex Pharma for $10 Million Blog Post

La farmacèutica Aerie Pharmaceuticals, que cotitza al Nasqad, ha annunciat l’adquisició d’Avizorex Pharma (AVX Pharma), amb seu al Parc Científic de Barcelona, per un import de 10 millones de dòlares. La companyia, fundada l’any 2013 com a spin-off de la Universitat Miguel Hernandez de Elche (UMH) per l’emprenedor Patrick Tresserras i el professor Carlos Belmonte de l’Institut de Neurociencias (UMH -CSIC), està especialitzada en el desenvolupament de teràpies innovadores per a la síndrome d’ull sec.